论文部分内容阅读
为了比较自体外周血干细胞移植 (APBSCT)与自体骨髓移植治疗CR1 期急性白血病的临床疗效 ,用APB SCT治疗 4 1例 ,用非净化自体骨髓移植 (ABMT)治疗 17例 ,用净化自体骨髓移植 (PABMT)治疗 30例。结果表明 :APBSCT组造血重建显著快于其他两组 ;3组全部病例的 3年无病存活率 (DFS) ,复发率 (RR)和移植相关死亡率(TRM)分别为 5 1.7% ,4 1.7%和 6 .8%。对DFS和RR产生显著影响的是白血病类型 (ALL或AML) ,确诊至CR1 的时间和CR1 至移植时间 3个因素 ;APBSCT组的 3年DFS ,RR和TRM分别为 4 8.4 % ,4 3.9%和 4 .9% ,ABMT组的DFS ,RR ,TRM分别为 4 7.1% ,4 5 .6 %和 11.8% ,PABMT组的DFS ,RR和TRM分别为 6 6 .5 % ,2 9 6 %和 6 .7% ,3组的疗效无显著差异。结论 :APBSCT治疗CR1 期急性白血病的疗效与ABMT和PABMT相当 ,但前者具有造血重建快、采集方便等优势 ,值得临床广泛推广。
In order to compare the clinical efficacy of autologous peripheral blood stem cell transplantation (APBSCT) and autologous bone marrow transplantation in the treatment of CR1 acute leukemia, 41 cases were treated with APB SCT, 17 cases were treated with non-purified autologous bone marrow transplantation (ABMT) PABMT) treatment of 30 cases. The results showed that the hematopoietic reconstitution in APBSCT group was significantly faster than the other two groups. The 3-year disease free survival (DFS), relapse rate (RR) and graft-related mortality (TRM) in all 3 groups were 51.7% % And 6 .8%. The three factors affecting the DFS and RR were leukemia type (ALL or AML), the time from diagnosis to CR1 and the time from CR1 to transplantation. The 3-year DFS, RR and TRM were 4 8.4% and 3.9% respectively in APBSCT group, And 4.9% respectively. The DFS, RR and TRM in ABMT group were 41.1%, 45.5% and 11.8%, respectively. The DFS, RR and TRM in PABMT group were 66.5% and 296% 6 .7%, no significant difference in the efficacy of the three groups. Conclusion: The curative effect of APBSCT on CR1 acute leukemia is similar to that of ABMT and PABMT. However, the former has the advantages of quick hematopoietic reconstitution, convenient collection and so on. It is worth widely popularizing in clinic.